stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.32
0.05
+0.95%
Follow RGC
Alert me
| Older periods | Jun '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
41.91 | 7.38 | 1.42 | 10.77 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(0.02) | (1.97) | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(4.01) | (3.27) | (2.59) | — | |
Working Capital |
7.92 | 4.24 | 0.69 | 12.90 | |
Capital Expenditures |
(0.01) | (0.15) | — | — | |
Net Current Asset Value |
7.89 | 4.01 | 0.56 | 12.84 | |
| Other line items | |||||
Quick Ratio |
41.12 | 7.38 | 1.42 | 10.74 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | — | — | |
Average Assets |
14.75 | 11.89 | 9.28 | 13.68 | |
Average Common Equity |
13.96 | 10.97 | 7.95 | 12.67 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026